Groundbreaking Lymphatic Interventions and Drug Exploration

---

Description

The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program through its Innovative Solutions Opening (ISO) ARPA-H-SOL-24-111. This program aims to accelerate the development of novel lymphatic system interventions and drug discovery efforts that can transform health outcomes. ARPA-H focuses on high-risk, high-reward biomedical research projects that traditional funding mechanisms may not pursue, with an emphasis on rapid translation from discovery to real-world impact within 3-5 years.

The GLIDE program seeks innovative approaches to understand, manipulate, and therapeutically target the lymphatic system, which plays a critical role in health and disease but remains underexplored. Proposals should present bold, transformative ideas that can lead to breakthrough technologies or therapies.

Due Dates

• December 12, 2024 — Updated Response Date for proposal submissions
• April 30, 2025 — Updated Inactive Date (deadline after which submissions will no longer be accepted)

Researchers should monitor the official solicitation page for any updates or amendments.

Funding Amount

• Total funding available is approximately $50 million.
• Funding will be awarded through cooperative agreements, supporting projects with significant potential for impact in lymphatic research and drug development.

Eligibility

Eligible applicants include:

• Public and state-controlled institutions of higher education
• Private institutions of higher education
• Nonprofit organizations with or without 501(c)(3) IRS status (excluding institutions of higher education)
• Individuals
• For-profit organizations other than small businesses
• Small businesses

This broad eligibility encourages diverse participation from academia, industry, and individual researchers.

Application Process

• The solicitation is posted as an Innovative Solutions Opening (ISO) on SAM.gov.
• Applicants must submit solution summaries and full proposals according to the timeline and instructions in the ISO ARPA-H-SOL-24-111.
• Attachments including templates for Target Product Profiles (TPP), pitch presentations, and cost proposal spreadsheets are provided to assist applicants.
• The full ISO supersedes any prior draft documents or presentations.
• Proposers are encouraged to review the FAQ and all attachments carefully to prepare competitive submissions.

Additional Information

• ARPA-H is a new federal agency within the Department of Health and Human Services, modeled after DARPA, with a mission to accelerate breakthrough health research.
• The GLIDE program specifically targets the lymphatic system, a relatively underexplored area with high potential for therapeutic innovation.
• The agency prioritizes projects that can deliver transformative health solutions within a short timeframe (3-5 years).
• The place of performance is Washington, DC, USA.
• Subaward reporting and entity validation processes are managed through SAM.gov.

External Links

• ARPA-H Official Website
• GLIDE Program Solicitation on SAM.gov
• GLIDE FAQ Document (archived)
• Attachment 1: GLIDE TPP Template and Examples
• Attachment 2: GLIDE Pitch Template v1.2
• Attachment 3a: ARPA-H Cost Proposal Spreadsheet (Cooperative Agreement)
• Attachment 3b: ARPA-H Cost Proposal Spreadsheet (Other Transaction)
• Subaward Reporting Transition Information
• Subaward Reports Help
• Subcontract Reports Help

Contact Information

Researchers interested in applying should direct technical or programmatic questions to the GLIDE team email.